Devyser wins all-time high tender for up to 75 MSEK

Devyser was awarded a five-year extension tender with the Toscana region in Italy for ten of its products. Devyser has also, via its distribution partner, been awarded the transplantation part of this tender. The indicative order value for Devyser is estimated to amount to approximately SEK 12-15 million annually.

"Winning this extended tender with the region of Toscana is a testament of the breadth, quality, and competitiveness of our product portfolio", said CEO Fredrik Alpsten. “I am extremely proud of the Italian team that made winning the largest tender in the history of Devyser possible, securing our business within this region for the next five years." 
The products included in the tender include Devyser CFTR, Devyser Thalassemia, Devyser RHD, several of the Devyser Oncology products, Devyser Compact plus, and last but not least via our distribution partner, the Devyser transplantation products.    

For more information, please contact:
Fredrik Alpsten, CEO 
E-mail: fredrik.alpsten@devyser.com
Telephone: +46 70 667 31 06
 
Theis Kipling, CCO
E-mail: theis.kipling@devyser.com 
Telephone: +46 73 598 07 76

About Devyser
Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.

Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.

Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB. 

Attachments
Devyser wins all-time high tender for up to 75 MSEK